Rallybio Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RLYB Nasdaq 2836 www.rallybio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rallybio Corporation

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Nov 6th, 2025 6:00 am
Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)? - Sep 27th, 2025 7:49 am
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Sep 25th, 2025 6:00 am
Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances - Sep 21st, 2025 7:26 am
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program - Sep 3rd, 2025 6:00 am
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid - Aug 17th, 2025 4:16 pm
Rallybio First Half 2025 Earnings: US$0.43 loss per share (vs US$0.83 loss in 1H 2024) - Aug 9th, 2025 6:34 am
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Aug 7th, 2025 6:00 am
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update - Aug 5th, 2025 4:30 am
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - Jul 20th, 2025 10:14 pm
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - Jul 17th, 2025 9:30 am
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Jul 9th, 2025 12:22 pm
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - Jul 9th, 2025 9:56 am
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Jul 9th, 2025 6:16 am
Sector Update: Health Care Stocks Advance Late Afternoon - Jul 8th, 2025 1:52 pm
Sector Update: Health Care Stocks Advance in Afternoon Trading - Jul 8th, 2025 11:57 am
Here's Why Shares in Recursion Pharmaceuticals Surged Today - Jul 8th, 2025 11:28 am
Top Midday Gainers - Jul 8th, 2025 11:28 am
Update: Recursion, Rallybio Shares Rise After Deal on Joint Hypophosphatasia Candidate - Jul 8th, 2025 10:07 am
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia - Jul 8th, 2025 6:00 am